System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Roy Fleischmann is an expert in Rheumatology at The University of Texas Southwestern Medical Center (United States). As of October 2026, ScienceLeadR ranks Roy Fleischmann in the top 1% of experts worldwide for Arthritis and Autoimmune Diseases. Roy Fleischmann has authored 533 publications, the most recent in 2026, and is an investigator in 56 clinical trials. SLR score: 2,584 (community average: 125). How the SLR is computed.

LeadR Profile

Roy Fleischmann The University of Texas Southwestern Medical Center United States
2 584 ScienceLeadR Reputation 2584

Unlock

Register Login
Network Map

Rheumatology

Subspecialties: Internal Medicine - Dermatology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1990 - 2026
Source: PubMed

The University of Texas Southwestern Medical Center

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 533

Citations

Citations: 32 840 1st author: 144 Last author: 96 Unique author: 45

Main journals

Ann Rheum Dis 177
Rheumatology (Oxford) 51
Arthritis Rheum 28
RMD Open 27
J Rheumatol 24

Best Journals

N Engl J Med 9
Nat Rev Rheumatol 3
Lancet 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study.
PMID 42342288 — safety, arthritis, rheumatic diseases, herpes zoster, arthritis, rheumatoid, adalimumab, therapeutics, non-responder		RMD Open20260
Response to correspondence on 'Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study' by Mysler et al.
PMID 42285872 — arthritis, rheumatic diseases, necrosis, arthritis, rheumatoid, adalimumab		Ann Rheum Dis20260
Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials).
PMID 42142212 — pain, arthritis, arthritis, rheumatoid, patient reported outcome measures, therapeutics		Rheumatol Ther20260
Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study.
PMID 41991443 — pain, arthritis, necrosis, arthritis, rheumatoid, adalimumab		Ann Rheum Dis20260
Baseline interleukin-10 levels as a predictive biomarker for achieving clinical response with abatacept in disease-modifying antirheumatic drug-naive and anticitrullinated protein antibody-positive patients with early rheumatoid arthritis.
PMID 41733109 — pharmaceutical preparations, antirheumatic agents, arthritis, biomarkers, abatacept, arthritis, rheumatoid, therapeutics, interleukin-10		Arthritis Rheumatol20260

Clinical Studies 56

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 32
Phase 2 10
Phase 4 7
Phase 1 6
Phase 2/Phase 3 1

By status:

Completed 52
Terminated 2
Active not recruiting 1
Unknown 1

By type:

Interventional 56

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 2
multicentric5to9 4
multicentricup10 43

Main Topics

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS